Florida Cancer Specialists Amplifies Industry Influence at FLASCO Summit
Event summary
- Florida Cancer Specialists (FCS) is participating in the FLASCO 2026 Spring Congress and Business of Oncology Summit in Orlando, April 10-11.
- Richard McDonough, MD, FCS’s director of advocacy & policy, will be a panelist discussing workforce transformation in oncology.
- FCS conducts over 180 active clinical trials annually, positioning it as a research leader.
- Dr. McDonough, a past president and current board member of FLASCO, is hosting a reception for fellows and residents.
The big picture
Florida Cancer Specialists’ active participation in FLASCO underscores the increasing importance of industry collaboration and advocacy in navigating the evolving oncology landscape. The company’s focus on clinical research and workforce development reflects broader trends toward precision medicine and addressing the growing demand for cancer care services, particularly as the population ages. FCS’s position as a leader in clinical trials provides a competitive advantage, but also increases its exposure to regulatory changes and payer pressures.
What we're watching
- Workforce Dynamics
- The discussion around workforce transformation at FLASCO will likely highlight the ongoing shortage of oncology professionals and the need for innovative training and retention strategies, potentially impacting care delivery models and costs.
- Research Funding
- FCS’s reliance on partnerships like Sarah Cannon Research Institute suggests a continued need for external funding to sustain its robust clinical trial program, making grant acquisition and collaborative agreements critical to its future growth.
- Policy Influence
- Dr. McDonough’s role in FLASCO and his advocacy focus indicate that FCS will actively shape policy discussions impacting oncology care in Florida, potentially influencing reimbursement rates and regulatory frameworks.
Related topics